Literature DB >> 24467735

Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter.

Wing Chiu Dai1, See Ching Chan, Kenneth S H Chok, Tan To Cheung, William W Sharr, Albert C Y Chan, Simon H Y Tsang, James Y Y Fung, Ronnie T P Poon, Sheung Tat Fan, Chung Mau Lo.   

Abstract

OBJECTIVES: There is controversy over whether hepatocellular carcinoma (HCC) should be primarily treated with living donor liver transplantation (LDLT) if liver resection (LR) can be effective. This retrospective study was conducted to compare survival outcomes in patients treated with either modality for solitary HCC measuring ≤8 cm in diameter.
METHODS: Outcomes in patients with solitary HCC primarily treated by LDLT were analysed. Patients with solitary HCC of similar sizes with or without microvascular invasion primarily treated with LR were selected at a ratio of 6 : 1 for comparison.
RESULTS: In-hospital mortality amounted to 0% and 1.3% in the LDLT (n = 50) and LR (n = 300) groups, respectively (P = 0.918). Complication rates were 34% and 20% in the LDLT and LR groups, respectively (P = 0.027). Rates of 1-, 3-, 5- and 10-year overall survival were 98%, 94%, 89% and 83%, respectively, in the LDLT group and 95%, 85%, 76% and 56%, respectively, in the LR group (P = 0.013). Rates of 1-, 3-, 5- and 10-year disease-free survival were 96%, 90%, 87% and 81%, respectively, in the LDLT group and 81%, 64%, 57% and 40%, respectively, in the LR group (P < 0.0001).
CONCLUSIONS: Living donor liver transplantation surpassed LR in survival outcomes, achieving a 10-year overall survival rate 1.5 times as high and a 10-year disease-free survival rate twice as high as those facilitated by LR. However, it entailed more complications, in addition to the inevitable risks to the donor.
© 2014 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2014        PMID: 24467735      PMCID: PMC4113258          DOI: 10.1111/hpb.12212

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  41 in total

1.  Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.

Authors:  Carlos Margarit; Alfredo Escartín; Lluis Castells; Víctor Vargas; Elena Allende; Itxarone Bilbao
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

2.  Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma?

Authors:  Leonidas G Koniaris; David M Levi; Felipe E Pedroso; Dido Franceschi; Andreas G Tzakis; Juan A Santamaria-Barria; Jennifer Tang; Marissa Anderson; Subhasis Misra; Naveenraj L Solomon; Xiaoling Jin; Peter J DiPasco; Margaret M Byrne; Teresa A Zimmers
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

3.  Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria.

Authors:  S T Fan; R T P Poon; C Yeung; C M Lam; C M Lo; W K Yuen; K K C Ng; C L Liu; S C Chan
Journal:  Br J Surg       Date:  2011-06-07       Impact factor: 6.939

4.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

5.  Liver transplantation for hepatocellular carcinoma in cirrhosis: prognostic parameters.

Authors:  C Benckert; S Jonas; A Thelen; A Spinelli; G Schumacher; M Heise; J Langrehr; P Neuhaus
Journal:  Transplant Proc       Date:  2005-05       Impact factor: 1.066

Review 6.  Liver transplantation for hepatocellular carcinoma: the Hong Kong experience.

Authors:  Kelvin K Ng; Chung Mau Lo; See Ching Chan; Kenneth S Chok; Tan-To Cheung; Sheung Tat Fan
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-09-17       Impact factor: 7.027

7.  Hepatocyte growth factor and transforming growth factor beta1 contribute to regeneration of small-for-size liver graft immediately after transplantation.

Authors:  Mizuki Ninomiya; Noboru Harada; Satoko Shiotani; Shoji Hiroshige; Ryosuke Minagawa; Yuji Soejima; Taketoshi Suehiro; Takashi Nishizaki; Mitsuo Shimada; Keizo Sugimachi
Journal:  Transpl Int       Date:  2003-07-15       Impact factor: 3.782

8.  Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection.

Authors:  Lian-Yue Yang; Feng Fang; Di-Peng Ou; Wei Wu; Zhi-Jun Zeng; Fan Wu
Journal:  Ann Surg       Date:  2009-01       Impact factor: 12.969

9.  Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases--activation of cell invasion and migration pathways.

Authors:  Kwan Man; Kevin T Ng; Chung Mau Lo; Joanna W Ho; Bai Shun Sun; Chris K Sun; Terence K Lee; Ronnie T P Poon; Sheung Tat Fan
Journal:  Liver Transpl       Date:  2007-12       Impact factor: 5.799

Review 10.  Liver transplantation for hepatocellular carcinoma in Asia.

Authors:  Vanessa de Villa; Chung Mau Lo
Journal:  Oncologist       Date:  2007-11
View more
  3 in total

1.  Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm.

Authors:  Wing Chiu Dai; Tan To Cheung; Kenneth S H Chok; Albert C Y Chan; William W Sharr; Simon H Y Tsang; Wai Key Yuen; See Ching Chan; Sheung Tat Fan; Chung Mau Lo; Ronnie T P Poon
Journal:  HPB (Oxford)       Date:  2014-10-06       Impact factor: 3.647

2.  Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities.

Authors:  Pegah Golabi; Sofie Fazel; Munkhzul Otgonsuren; Mehmet Sayiner; Cameron T Locklear; Zobair M Younossi
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

3.  Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels.

Authors:  Wong Hoi She; Albert Chi Yan Chan; Tan To Cheung; Chung Mau Lo; Kenneth Siu Ho Chok
Journal:  World J Hepatol       Date:  2018-02-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.